Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
176.70
-3.40 (-1.89%)
At close: Apr 2, 2026

HKG:2637 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
582.36466.68316.63212.47
Revenue Growth (YoY)
24.79%47.39%49.03%-
Cost of Revenue
96.879.4952.9940.39
Gross Profit
485.56387.19263.64172.07
Selling, General & Admin
219.79186.64107.356.9
Research & Development
73.567.5336.0634.82
Operating Expenses
293.3254.17143.3691.72
Operating Income
192.26133.03120.2880.35
Interest Expense
-5.74-7.22-7.75-24.73
Interest & Investment Income
-5.647.096.39
Other Non Operating Income (Expenses)
11.5516.4113.2311.92
EBT Excluding Unusual Items
198.08147.85132.8573.92
Gain (Loss) on Sale of Investments
-1.14--0.14
Gain (Loss) on Sale of Assets
---0.03-0.02
Pretax Income
198.08148.99132.8173.76
Income Tax Expense
21.0512.9215.364.78
Net Income
177.03136.08117.4568.98
Net Income to Common
177.03136.08117.4568.98
Net Income Growth
30.09%15.86%70.27%-
Shares Outstanding (Basic)
69676764
Shares Outstanding (Diluted)
69676764
Shares Change (YoY)
3.30%-4.57%-
EPS (Basic)
2.552.021.751.07
EPS (Diluted)
2.552.021.751.07
EPS Growth
25.94%15.86%62.83%-
Free Cash Flow
--14.6288.3982.24
Free Cash Flow Per Share
--0.221.311.28
Gross Margin
83.38%82.97%83.26%80.99%
Operating Margin
33.01%28.51%37.99%37.82%
Profit Margin
30.40%29.16%37.09%32.47%
Free Cash Flow Margin
--3.13%27.92%38.71%
EBITDA
195.19135.96122.6182.23
EBITDA Margin
33.52%29.13%38.72%38.70%
D&A For EBITDA
2.932.932.331.88
EBIT
192.26133.03120.2880.35
EBIT Margin
33.01%28.51%37.99%37.82%
Effective Tax Rate
10.63%8.67%11.56%6.48%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.